Chargement en cours...
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102)
Trifluridine/tipiracil (TAS-102) is a new oral combination therapy approved by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer who are refractory to or intolerant of standard chemotherapy. This agent consists of a thymidine-based nucleoside analog...
Enregistré dans:
| Publié dans: | Clin Colorectal Cancer |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5743195/ https://ncbi.nlm.nih.gov/pubmed/28242161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2017.01.003 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|